SMC bars access to Actelion’s Uptravi on NHS Scotland
Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.
Read More
Tag: Qtern
AZ’ diabetes therapy Qtern wins US nod
The US Food and Drug Administration has now issued a green light for the use of AstraZeneca’s diabetes combination therapy Qtern to treat patients with type II diabetes, having rejected it back in 2015 with a request for more clinical data.
Read More
UK sees first global launch of AZ’ diabetes combo Qtern
Adults in the UK with type II diabetes have gained a new treatment option to keep blood sugar levels under control with the launch of AstraZeneca’s Qtern in the country.
Read More
EU nod for AZ’ diabetes therapy Qtern
The European Commission has green-lighted Qtern (saxagliptin/dapagliflozin) for the treatment of type II diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway.
Read More
Six medicines win backing for EU approval
Six medicines, including two new combination therapies for chronic hepatitis C, are lining up for EU approval after having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
